

# Stephen M Stahl

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5523834/stephen-m-stahl-publications-by-citations.pdf>

**Version:** 2024-02-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

193  
papers

5,122  
citations

40  
h-index

69  
g-index

233  
ext. papers

6,589  
ext. citations

3.6  
avg, IF

6.47  
L-index

#	Paper	IF	Citations
193	Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. <i>Journal of Affective Disorders</i> , <b>1998</b> , 51, 215-35	6.6	360
192	SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. <i>CNS Spectrums</i> , <b>2005</b> , 10, 732-47	1.8	353
191	A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , <b>2004</b> , 6, 159-166		293
190	Mechanism of action of trazodone: a multifunctional drug. <i>CNS Spectrums</i> , <b>2009</b> , 14, 536-46	1.8	219
189	Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. <i>Journal of Sexual Medicine</i> , <b>2011</b> , 8, 15-27	1.1	160
188	Serotonergic drugs for depression and beyond. <i>Current Drug Targets</i> , <b>2013</b> , 14, 578-85	3	148
187	The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities?. <i>Trends in Pharmacological Sciences</i> , <b>2013</b> , 34, 332-9	13.2	145
186	Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, 616-26	4.6	142
185	Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. <i>CNS Spectrums</i> , <b>2008</b> , 13, 1027-38	1.8	126
184	Mirtazapine: An Antidepressant with Noradrenergic and Specific Serotonergic Effects. <i>Pharmacotherapy</i> , <b>1997</b> , 17, 10-21	5.8	112
183	The psychopharmacology of energy and fatigue. <i>Journal of Clinical Psychiatry</i> , <b>2002</b> , 63, 7-8	4.6	105
182	Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. <i>CNS Spectrums</i> , <b>2008</b> , 13, 855-70	1.8	103
181	Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Psychiatry</i> , <b>2003</b> , 64, 1322-7	4.6	103
180	Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review. <i>Mayo Clinic Proceedings</i> , <b>2017</b> , 92, 114-128	6.4	102
179	Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties. <i>CNS Spectrums</i> , <b>2014</b> , 19, 207-12	1.8	95
178	Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?. <i>Journal of Clinical Psychiatry</i> , <b>1999</b> , 60, 425-6	4.6	92
177	A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 2318-25	1.2	89

176	Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data. <i>Therapeutic Advances in Psychopharmacology</i> , <b>2020</b> , 10, 2045125320905752	4.9	86
175	Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies. <i>CNS Spectrums</i> , <b>2020</b> , 25, 502-510	1.8	84
174	How to dose a psychotropic drug: beyond therapeutic drug monitoring to genotyping the patient. <i>Acta Psychiatrica Scandinavica</i> , <b>2010</b> , 122, 440-1	6.5	80
173	Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Psychopharmacology</i> , <b>2010</b> , 30, 135-44	1.7	79
172	Understanding pain in depression. <i>Human Psychopharmacology</i> , <b>2004</b> , 19 Suppl 1, S9-S13	2.3	74
171	Guidelines for the recognition and management of mixed depression. <i>CNS Spectrums</i> , <b>2017</b> , 22, 203-219	1.8	72
170	Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. <i>CNS Spectrums</i> , <b>2004</b> , 9, 6-14	1.8	67
169	Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. <i>Neurotherapeutics</i> , <b>2009</b> , 6, 78-85	6.4	66
168	Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. <i>CNS Spectrums</i> , <b>2007</b> , 12, 265-8	1.8	64
167	Does depression hurt?. <i>Journal of Clinical Psychiatry</i> , <b>2002</b> , 63, 273-4	4.6	62
166	A proposal for an updated neuropsychopharmacological nomenclature. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, 1005-14	1.2	60
165	Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent. <i>CNS Spectrums</i> , <b>2007</b> , 12, 739-44	1.8	55
164	Drug research: a plan for mental illness. <i>Nature</i> , <b>2012</b> , 483, 269	50.4	53
163	Long-acting injectable antipsychotics: shall the last be first?. <i>CNS Spectrums</i> , <b>2014</b> , 19, 3-5	1.8	50
162	Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. <i>CNS Spectrums</i> , <b>2005</b> , 10, 319-23	1.8	47
161	Meta-guidelines for the management of patients with schizophrenia. <i>CNS Spectrums</i> , <b>2013</b> , 18, 150-162	1.8	46
160	High-cost use of second-generation antipsychotics under California's Medicaid program. <i>Psychiatric Services</i> , <b>2006</b> , 57, 127-9	3.3	46
159	Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability. <i>American Journal of Medicine</i> , <b>2015</b> , 128, S1-S15	2.4	45

158	Multifunctional drugs: a novel concept for psychopharmacology. <i>CNS Spectrums</i> , <b>2009</b> , 14, 71-3	1.8	43
157	Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. <i>Journal of Clinical Psychiatry</i> , <b>2013</b> , 74, 507-15	4.6	43
156	Does evidence from clinical trials in psychopharmacology apply in clinical practice?. <i>Journal of Clinical Psychiatry</i> , <b>2001</b> , 62, 6-7	4.6	41
155	Antipsychotic polypharmacy: squandering precious resources?. <i>Journal of Clinical Psychiatry</i> , <b>2002</b> , 63, 93-4	4.6	40
154	Fibromyalgia--pathways and neurotransmitters. <i>Human Psychopharmacology</i> , <b>2009</b> , 24 Suppl 1, S11-7	2.3	36
153	The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. <i>Journal of Clinical Psychiatry</i> , <b>2003</b> , 64 Suppl 19, 6-12	4.6	35
152	Modulating the serotonin system in the treatment of major depressive disorder. <i>CNS Spectrums</i> , <b>2014</b> , 19 Suppl 1, 57-67; quiz 54-7, 68	1.8	32
151	Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. <i>Current Medical Research and Opinion</i> , <b>2004</b> , 20, 517-24	2.5	31
150	Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. <i>Current Medical Research and Opinion</i> , <b>2007</b> , 23, 2815-22	2.5	30
149	Case Studies: Stahl's Essential Psychopharmacology <b>2011</b> ,		29
148	Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. <i>CNS Spectrums</i> , <b>2010</b> , 15, 79-94	1.8	28
147	Effectiveness of ipsapirone, a 5-HT-1A partial agonist, in major depressive disorder: support for the role of 5-HT-1A receptors in the mechanism of action of serotonergic antidepressants. <i>International Journal of Neuropsychopharmacology</i> , <b>1998</b> , 1, 11-18	5.8	28
146	Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence?. <i>International Journal of Neuropsychopharmacology</i> , <b>2004</b> , 7, 113-6	5.8	25
145	Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials. <i>Journal of Clinical Psychopharmacology</i> , <b>2002</b> , 22, 388-92	1.7	25
144	The psychopharmacology of sex, Part 1: Neurotransmitters and the 3 phases of the human sexual response. <i>Journal of Clinical Psychiatry</i> , <b>2001</b> , 62, 80-1	4.6	25
143	California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. <i>CNS Spectrums</i> , <b>2014</b> , 19, 449-465	1.8	23
142	Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. <i>CNS Spectrums</i> , <b>2014</b> , 19, 439-48	1.8	23
141	Antipsychotic polypharmacy, part 2: tips on use and misuse. <i>Journal of Clinical Psychiatry</i> , <b>1999</b> , 60, 506-7	4.6	23

140	The last Diagnostic and Statistical Manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental illnesses. <i>CNS Spectrums</i> , <b>2013</b> , 18, 65-8	1.8	22
139	Treatment strategies for dosing the second generation antipsychotics. <i>CNS Neuroscience and Therapeutics</i> , <b>2011</b> , 17, 110-7	6.8	20
138	A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. <i>Journal of Clinical Psychopharmacology</i> , <b>2010</b> , 30, 425-30	1.7	20
137	Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. <i>International Journal of Neuropsychopharmacology</i> , <b>2007</b> , 10, 575-8	5.8	20
136	Antipsychotic drug development. <i>Current Topics in Behavioral Neurosciences</i> , <b>2010</b> , 4, 123-39	3.4	19
135	Novel therapeutics for schizophrenia: targeting glycine modulation of NMDA glutamate receptors. <i>CNS Spectrums</i> , <b>2007</b> , 12, 423-7	1.8	19
134	Progressive myelopathy due to extramedullary hematopoiesis: case report and review of the literature. <i>Annals of Neurology</i> , <b>1979</b> , 5, 485-9	9.4	19
133	Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER. <i>CNS Spectrums</i> , <b>2007</b> , 12, 703-11	1.8	18
132	Using secondary binding properties to select a not so selective serotonin reuptake inhibitor. <i>Journal of Clinical Psychiatry</i> , <b>1998</b> , 59, 642-3	4.6	18
131	The potential role of a corticotropin-releasing factor receptor-1 antagonist in psychiatric disorders. <i>CNS Spectrums</i> , <b>2008</b> , 13, 467-83	1.8	17
130	Psychopharmacology of Persistent Violence and Aggression. <i>Psychiatric Clinics of North America</i> , <b>2016</b> , 39, 541-556	3.1	16
129	Pharmacotherapy of cognitive deficits in schizophrenia. <i>CNS Spectrums</i> , <b>2014</b> , 19, 142-56	1.8	16
128	Sleep electroencephalographic response to muscarinic and serotonin1A receptor probes in patients with major depression and in normal controls. <i>Biological Psychiatry</i> , <b>1998</b> , 44, 21-33	7.9	16
127	Do dopamine partial agonists have partial efficacy as antipsychotics?. <i>CNS Spectrums</i> , <b>2008</b> , 13, 279-82	1.8	16
126	Finding what you are not looking for: strategies for developing novel treatments in psychiatry. <i>NeuroRx</i> , <b>2006</b> , 3, 3-9		15
125	Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity. <i>CNS Spectrums</i> , <b>2019</b> , 24, 461-466	1.8	14
124	Personalized medicine, pharmacogenomics, and the practice of psychiatry: on the threshold of predictive therapeutics in psychopharmacology?. <i>CNS Spectrums</i> , <b>2008</b> , 13, 115-8	1.8	13
123	Differences in mechanism of action between current and future antidepressants. <i>Journal of Clinical Psychiatry</i> , <b>2003</b> , 64 Suppl 13, 13-7	4.6	13

122	Psychiatric stress testing: novel strategy for translational psychopharmacology. <i>Neuropsychopharmacology</i> , <b>2010</b> , 35, 1413-4	8.7	12
121	Selectivity of SSRIs: individualising patient care through rational treatment choices. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2004</b> , 8 Suppl 1, 3-10	2.4	12
120	Antidepressants and somatic symptoms: therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromes. <i>Journal of Clinical Psychiatry</i> , <b>2003</b> , 64, 745-6	4.6	12
119	Mixed-up about how to diagnose and treat mixed features in major depressive episodes. <i>CNS Spectrums</i> , <b>2017</b> , 22, 111-115	1.8	11
118	Ziprasidone hydrochloride: what role in the management of schizophrenia?. <i>Journal of Central Nervous System Disease</i> , <b>2011</b> , 3, 1-16	4.4	11
117	Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment. <i>CNS Spectrums</i> , <b>2012</b> , 17 Suppl 1, 10-21	1.8	11
116	The genetics of schizophrenia converge upon the NMDA glutamate receptor. <i>CNS Spectrums</i> , <b>2007</b> , 12, 583-8	1.8	11
115	Inverse agonists - What do they mean for psychiatry?. <i>European Neuropsychopharmacology</i> , <b>2017</b> , 27, 87-90	1.2	10
114	Fooling mother nature: epigenetics and novel treatments for psychiatric disorders. <i>CNS Spectrums</i> , <b>2010</b> , 15, 358-65	1.8	10
113	Ciprofloxacin and Clozapine: A Potentially Fatal but Underappreciated Interaction. <i>Case Reports in Psychiatry</i> , <b>2016</b> , 2016, 5606098	0.6	10
112	Off-label prescribing: best practice or malpractice?. <i>CNS Spectrums</i> , <b>2013</b> , 18, 1-4	1.8	9
111	Expert Consensus on Screening and Assessment of Cognition in Psychiatry. <i>CNS Spectrums</i> , <b>2019</b> , 24, 154-162	1.8	9
110	REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial.. <i>American Journal of Psychiatry</i> , <b>2021</b> , appiajp202121020197	11.9	8
109	Prescriber's Guide <b>2020</b> ,		7
108	Gut feelings about irritable bowel syndrome. <i>Journal of Clinical Psychiatry</i> , <b>2001</b> , 62, 590-1	4.6	7
107	Biochemical pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands. <i>International Review of Psychiatry</i> , <b>1995</b> , 7, 55-67	3.6	6
106	Mixed mood states: Baffled, bewildered, befuddled and bemused. <i>Bipolar Disorders</i> , <b>2019</b> , 21, 560-561	3.8	5
105	Crisis in army psychopharmacology and mental health care at Fort Hood. <i>CNS Spectrums</i> , <b>2009</b> , 14, 677-84	4.8	5

104	Applying the principles of adult learning to the teaching of psychopharmacology: overview and finding the focus. <i>CNS Spectrums</i> , <b>2009</b> , 14, 179-82	1.8	5
103	Mirror, mirror on the wall, which enantiomer is fairest of them all?. <i>Journal of Clinical Psychiatry</i> , <b>2002</b> , 63, 656-7	4.6	5
102	Drug information update. Unconventional treatment strategies for schizophrenia: polypharmacy and heroic dosing. <i>BJPsych Bulletin</i> , <b>2017</b> , 41, 164-168	1.2	4
101	Nefazodone and the serotonin receptor modulators: a new member of a unique class of antidepressant agents. <i>International Review of Psychiatry</i> , <b>1995</b> , 7, 29-39	3.6	4
100	At long last, long-lasting psychiatric medications: an overview of controlled-release technologies. <i>Journal of Clinical Psychiatry</i> , <b>2003</b> , 64, 355-6	4.6	4
99	Serotonin and Love: Supporting Evidence From a Patient Suffering From Obsessive-Compulsive Disorder. <i>Journal of Clinical Psychopharmacology</i> , <b>2018</b> , 38, 99-101	1.7	4
98	Fibromyalgia: the enigma and the stigma. <i>Journal of Clinical Psychiatry</i> , <b>2001</b> , 62, 501-2	4.6	3
97	REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 671859	5.6	3
96	Precision and personalized assessment, diagnosis and treatment in psychiatry. <i>CNS Spectrums</i> , <b>2021</b> , 26, 326-332	1.8	3
95	Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. <i>CNS Spectrums</i> , <b>2018</b> , 23, 402-413	1.8	3
94	New Medications for Neuropsychiatric Disorders. <i>Psychiatric Clinics of North America</i> , <b>2020</b> , 43, 399-413	3.1	2
93	Conditions of life and death of psychiatric patients in France during World War II: euthanasia or collateral casualties?. <i>CNS Spectrums</i> , <b>2018</b> , 23, 170-175	1.8	2
92	Mental energy: plausible neurological mechanisms and emerging research on the effects of natural dietary compounds. <i>Nutritional Neuroscience</i> , <b>2021</b> , 24, 850-864	3.6	2
91	Does a "whiff" of mania in a major depressive episode shift treatment from a classical antidepressant to an atypical/second-generation antipsychotic?. <i>Bipolar Disorders</i> , <b>2017</b> , 19, 595-596	3.8	2
90	Applying the principles of adult learning to the teaching of psychopharmacology: storyboarding a presentation and the rule of small multiples. <i>CNS Spectrums</i> , <b>2009</b> , 14, 288-94	1.8	2
89	Overview of trends in modern psychopharmacology. <i>CNS Spectrums</i> , <b>2007</b> , 12, 103-5	1.8	2
88	Applying the principles of adult learning to the teaching of psychopharmacology: audience response systems. <i>CNS Spectrums</i> , <b>2009</b> , 14, 412-4	1.8	2
87	Pharmacologic Treatment of Mixed States. <i>Psychiatric Clinics of North America</i> , <b>2020</b> , 43, 167-186	3.1	2

86	Dementia-related psychosis and the potential role for pimavanserin. <i>CNS Spectrums</i> , <b>2020</b> , 1-9	1.8	2
85	How and when to treat the most common adverse effects of antipsychotics: Expert review from research to clinical practice. <i>Acta Psychiatrica Scandinavica</i> , <b>2021</b> , 143, 172-180	6.5	2
84	Flibanserin - the female Viagra?. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2017</b> , 21, 259-265	2.4	1
83	Emerging guidelines for the use of antipsychotic polypharmacy. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , <b>2013</b> , 6, 97-100	0.2	1
82	Why psychiatrists should not ignore pain in their patients--focus on fibromyalgia?. <i>Human Psychopharmacology</i> , <b>2009</b> , 24 Suppl 1, S1-2	2.3	1
81	A horse of a different color: how formulation influences medication effects. <i>CNS Spectrums</i> , <b>2012</b> , 17, 63-9	1.8	1
80	Cariprazine <b>2020</b> , 137-146		1
79	Early response to trazodone once-a-day in major depressive disorder: review of the clinical data and putative mechanism for faster onset of action. <i>CNS Spectrums</i> , <b>2021</b> , 26, 232-242	1.8	1
78	Psychopharmacology and ethnicity: A comparative study on Senegalese and Italian men. <i>World Journal of Biological Psychiatry</i> , <b>2020</b> , 21, 300-307	3.8	1
77	Pharmacology: policy implications of new psychiatric drugs. <i>Health Affairs</i> , <b>1992</b> , 11, 157-63	0	0
76	The effect of first- and second-generation antipsychotics on brain morphology in schizophrenia: A systematic review of longitudinal magnetic resonance studies with a randomized allocation to treatment arms.. <i>Journal of Psychopharmacology</i> , <b>2022</b> , 2698811221087645	4.6	0
75	Genetics and Epigenetics of Mental Illness: Implications for Diagnosis and Treatment <b>2014</b> , 1-9		
74	Psychopharmacology: Child and Adolescent <b>2015</b> , 1-14		
73	Evidence-based pharmacotherapy of major depressive disorder53-72		
72	Evidence-based pharmacotherapy of panic disorder73-89		
71	Ziprasidone in the Treatment of Bipolar Disorder <b>2011</b> , 223-244		
70	Molecular and Cellular Biology Research in Psychiatry29-58		
69	Imipramine <b>2020</b> , 367-374		

68 Molindone **2020**, 527-532

67 Diphenhydramine **2020**, 235-238

66 Acamprosate **2020**, 1-4

65 Flunitrazepam **2020**, 297-300

64 Lumateperone **2020**, 451-456

63 Galantamine **2020**, 337-342

62 Flumazenil **2020**, 293-296

61 Flupenthixol **2020**, 307-312

60 Asenapine **2020**, 71-78

59 Lofepramine **2020**, 421-426

58 Armodafinil **2020**, 65-70

57 Amoxapine

56 Brexanolone **2020**, 99-102

55 Chlordiazepoxide **2020**, 147-152

54 Lurasidone **2020**, 457-464

53 Deutetrabenazine **2020**, 221-224

52 Nefazodone **2020**, 545-550

51 Dothiepin **2020**, 249-254

50 Lemborexant

49 Mianserin **2020**, 495-498

48 Moclobemide **2020**, 515-520

47 Buspirone **2020**, 123-126

46 Agomelatine

45 Oxazepam **2020**, 569-574

44 Desvenlafaxine **2020**, 215-220

43 Desipramine **2020**, 207-214

42 Memantine

41 Isocarboxazid **2020**, 375-382

40 Nalmefene **2020**, 533-536

39 Dextromethorphan **2020**, 225-228

38 Methylphenidate (D,L) **2020**, 487-494

37 Naltrexone **2020**, 537-540

36 Levomilnacipran **2020**, 403-408

35 loperidone **2020**, 359-366

34 Nortriptyline **2020**, 551-558

33 Blonanserin **2020**, 89-94

32 Maprotiline **2020**, 465-472

31 Amphetamine (D,L) **2020**, 45-52

30 Doxepin **2020**, 255-262

29 Methylphenidate (D) **2020**, 481-486

28 Guanfacine **2020**, 343-346

27 Methylfolate (L) **2020**, 477-480

26 Brexpiprazole

25 Hydroxyzine **2020**, 355-358

24 Esketamine **2020**, 275-280

23 Alprazolam **2020**, 11-16

22 Estazolam **2020**, 281-284

21 Lisdexamfetamine

20 Flurazepam **2020**, 321-324

19 Cyamemazine **2020**, 201-206

18 Amphetamine (D) **2020**, 39-44

17 Amitriptyline **2020**, 25-32

16 Caprylidene **2020**, 127-130

15 Eszopiclone **2020**, 285-288

14 Bremelanotide **2020**, 95-98

13 Milnacipran **2020**, 503-508

12 Flibanserin **2020**, 289-292

11 Loxapine **2020**, 443-450

10 Fluphenazine **2020**, 313-320

9 Clomipramine **2020**, 165-172

8 Fluvoxamine **2020**, 325-330

7 Modafinil **2020**, 521-526

6 Amisulpride **2020**, 17-24

5 Bzotropine **2020**, 85-88

4 Lofexidine **2020**, 427-430

3 Should High Dose or Very Long-Term Antipsychotic Monotherapy Be Considered Before Antipsychotic Polypharmacy? **2013**, 107-125

2 Response to the Letter to the Editor "Psychiatry's undeclared identity crisis in a changing world" by Richard Skaff. *CNS Spectrums*, **2021**, 1-2 1.8

1 Loflazepate **2020**, 431-436